NCT02124447

Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy

Comparison of Efficacy and Patient Tolerability of Four Commercially Available Bowel Purgatives for Screening and Surveillance Colonoscopy: A Single Tertiary Medical Center Experience.

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Medical College of Wisconsin · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This will be a 4-way comparison to prospectively evaluate the efficacy and patient tolerability of four commercially available bowel preparations among patients undergoing colonoscopy for screening and surveillance in a single tertiary academic medical center.

Detailed description

We will randomize 300 consecutive patients undergoing colonoscopy for screening or surveillance purposes to receive one of four bowel purgatives. These purgatives include 1. Split dose 4 liter polyethylene glycol with electrolytes (PEG+E): Brand name GoLytely 2. Split dose 2 liter polyethylene glycol with ascorbic acid (PEG+Asc): Brand name: MoviPrep 3. Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid (P+MC): Brand name Prepopik 4. Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution (sulfate): Brand name Suprep

Conditions

• Patients Undergoing Screening or Surveillance Colonoscopy

Interventions

Type	Name	Description
DRUG	PEG+E	Split dose 4 liter polyethylene glycol with electrolytes
DRUG	PEG+Asc	Split dose 2 liter polyethylene glycol with ascorbic acid
DRUG	P+MC	Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
DRUG	sulfate	Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution

Timeline

• Start date: 2014-06-01
• Primary completion: 2014-08-01
• Completion: 2015-06-01
• First posted: 2014-04-28
• Last updated: 2015-07-10

Locations

1 site across 1 country: United States